Han Tao, Song Linhong, Niu Xinxin, Qiu Meng, Wang Yi, Wang Jing, Sun Xiuyan, Ma Jiali, Hu Siqi, Feng Zhichun
Department of Neonatology, Senior Department of Pediatrics, the Seventh Medical Center of Chinese PLA General Hospital, China.
Department of Pediatric Cardiac Surgery, Senior Department of Pediatrics, the Seventh Medical Center of Chinese PLA General Hospital, China.
Heliyon. 2024 Apr 29;10(9):e30489. doi: 10.1016/j.heliyon.2024.e30489. eCollection 2024 May 15.
The SARS-CoV-2, responsible for the COVID-19 pandemic, poses a significant threat to global healthcare. Peptide and peptide-based inhibitors, known for their safety, efficacy, and selectivity, have recently emerged as promising candidates for treating late-developing viral infections. In this study, three peptides were selected to target different stages of viral invasion, specifically ACE2 and S protein binding, as well as membrane fusion. The objective was to assess their ability to impede the entry of the SARS-CoV-2 Spike pseudotyped virus. Our findings revealed that a combination of these three peptides demonstrated enhanced antiviral effects. This outcome substantiates the feasibility of developing effective peptide combinations to combat diseases related to SARS-CoV-2. Moreover, the three-peptide combinations, designed to target multiple aspects of SARS-CoV-2 viral entry, exhibited heightened viral inhibition and broad-spectrum antiviral properties.
导致新冠疫情的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）对全球医疗保健构成重大威胁。肽和基于肽的抑制剂因其安全性、有效性和选择性而闻名，最近已成为治疗后期出现的病毒感染的有希望的候选药物。在本研究中，选择了三种肽来靶向病毒入侵的不同阶段，特别是血管紧张素转换酶2（ACE2）和刺突蛋白（S蛋白）结合以及膜融合。目的是评估它们阻止SARS-CoV-2刺突假型病毒进入的能力。我们的研究结果表明，这三种肽的组合显示出增强的抗病毒效果。这一结果证实了开发有效的肽组合来对抗与SARS-CoV-2相关疾病的可行性。此外，旨在靶向SARS-CoV-2病毒进入多个方面的三肽组合表现出更高的病毒抑制作用和广谱抗病毒特性。
